000			03579nam a22004095i 4500
999			_c82058 _d82058 _x1
001			82058
003			ES-MaUEC
005			20230207040353.0
007			cr nn 008mamaa
008			141124s2015 xxua s 001 0 eng d
020			_a9781493921430
024	7		_a10.1007/978-1-4939-2143-0 _2doi
040			_cES-MaUEC
050		4	_aRC280.M37 _b2015 EB
082	0	4	_a614.5999
245	0	0	_aBRAF Targets in Melanoma : _bBiological Mechanisms, Resistance, and Drug Discovery _cedited by Ryan J. Sullivan
260			_aNew York _bSpringer _c2015
300			_a1 recurso en línea (VIII, 204 p.) _b26 ilustraciones, 21 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	1		_aCancer Drug Discovery and Development _x2196-9906 _v82
505	0		_aMelanoma: Historical Context -- Melanoma Pathogenesis -- Molecular Diagnostics and Tumor Mutational Analysis -- Clinical Utility of BRAF-targeted therapy in Melanoma -- The Ethics of Randomized Trials in Oncology -- Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma -- Targeting the cell cycle and p53 in combination with BRAF-directed therapy -- Combination BRAF-directed therapy and immunotherapy -- Moving Forward: Making BRAF-Targeted Therapy Better.
520	3		_aThis volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma.
650		7	_aMelanoma _xTratamiento _9143713 _0comprobar BNE19942553083 _2embne
650		7	_aCáncer _xInvestigación _0comprobar BNE19901364217 _2embne _9182523
700	1		_aSullivan, Ryan J _eeditor literario _994714 _0Local
710	2		_aSpringerLink (Online service) _0Local _9106996
830		0	_aCancer Drug Discovery and Development _x2196-9906 _v82 _9133188
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4939-2143-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9781493921430
907			_a.b12906979 _b10-10-17 _c10-02-16
942			_2lcc _cLE
945			_aRC280 .M37 B73 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11574665 _z06-04-17
988			_aSpringer_Medicine_2015
998			_am _a_alco _a_vill _b13-07-17 _cm _dz _ea _feng _gxxu _h0